Hybrid (2D/3D) Dosimetry of Radiolabeled Gold Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer

Table 3

Average equivalent and effective doses (mSv/MBq) of^99mTc-AuNP-mannose, calculated from five patients with breast cancer.

Target organ	Equivalent doses (mean ± SD)
	Hybrid 2D/3D	2D
Adrenals	1.28E − 03 ± 1.60E − 04	1.34E − 03 ± 1.20E − 04
Brain	3.46E − 04 ± 9.85E − 05	3.14E − 04 ± 8.08E − 05
Breasts	1.44E − 01 ± 1.00E − 02	1.51E − 01 ± 8.67E − 03
Gallbladder wall	1.06E − 03 ± 1.61E − 04	1.08E − 03 ± 1.25E − 04
LLI wall	5.84E − 04 ± 1.25E − 04	5.63E − 04 ± 1.28E − 04
Small intestine	5.99E − 04 ± 1.27E − 04	5.86E − 04 ± 1.15E − 04
Stomach wall	1.45E − 03 ± 1.77E − 04	1.48E − 03 ± 1.24E − 04
ULI wall	6.76E − 04 ± 1.37E − 04	6.63E − 04 ± 1.18E − 04
Heart wall	4.70E − 03 ± 3.94E − 04	4.88E − 03 ± 2.96E − 04
Kidneys	2.03E − 03 ± 3.31E − 04	3.02E − 03 ± 7.98E − 04
Liver	1.56E − 03 ± 1.79E − 04	1.60E − 03 ± 1.27E − 04
Lungs	3.61E − 03 ± 3.13E − 04	3.74E − 03 ± 2.31E − 04
Muscle	1.05E − 03 ± 1.30E − 04	1.06E − 03 ± 9.70E − 05
Ovaries	5.92E − 04 ± 1.28E − 04	5.71E − 04 ± 1.30E − 04
Pancreas	1.47E − 03 ± 1.84E − 04	1.51E − 03 ± 1.33E − 04
Red marrow	1.12E − 03 ± 1.38E − 04	1.14E − 03 ± 9.83E − 05
Osteogenic cells	2.22E − 03 ± 3.59E − 04	2.19E − 03 ± 2.74E − 04
Skin	1.38E − 03 ± 1.33E − 04	1.42E − 03 ± 9.54E − 05
Spleen	1.13E − 03 ± 1.47E − 04	1.18E − 03 ± 1.08E − 04
Thymus	4.46E − 03 ± 3.70E − 04	4.63E − 03 ± 2.84E − 04
Thyroid	8.18E − 04 ± 1.25E − 04	8.08E − 04 ± 9.38E − 05
Urinary bladder wall	2.88E − 03 ± 8.72E − 04	3.27E − 03 ± 1.12E − 03
Uterus	7.03E − 04 ± 1.26E − 04	7.04E − 04 ± 1.61E − 04
Sentinel lymph node	4.66E + 00 ± 6.73E − 01	2.63E + 00 ± 1.04E + 0
Effective dose (mSv/MBq)	2.05E − 03 ± 1.92E − 04	2.12E − 03 ± 1.38E − 04